Engineering and evaluation of precision-glycosylated clickable albumin nanoplatform for targeting the tumor microenvironment
Engineering and evaluation of precision-glycosylated clickable albumin nanoplatform for targeting the tumor microenvironment
Dihydroartemisinin inhibits metastatic potential and cancer stemness by modulating the miR-200b-BMI-1/VEGF-A axis in ovarian cancer
Dihydroartemisinin inhibits metastatic potential and cancer stemness by modulating the miR-200b-BMI-1/VEGF-A axis in ovarian cancer
Evaluation of false positive and false negative errors in targeted next generation sequencing
Evaluation of false positive and false negative errors in targeted next generation sequencing
Genome Biol., DOI: 10.1186/s13059-025-03882-2
2025-12
의약학
한빛사논문
Shujin Li/upload/board/files/hbs_author/author_2/0042252_1.png(연세대학교)Shujin Li / 정한성
Modulation of the tumor microenvironment through BMAL1-LHX8 axis augments the sensitivity of ameloblastoma to vemurafenib
Modulation of the tumor microenvironment through BMAL1-LHX8 axis augments the sensitivity of ameloblastoma to vemurafenib
A Novel Prognostic Model for Primary CNS Lymphoma Incorporating Clinico-Laboratory Parameters
A Novel Prognostic Model for Primary CNS Lymphoma Incorporating Clinico-Laboratory Parameters
Open-label, single-arm, phase 2 trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer
Open-label, single-arm, phase 2 trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer
Nutrient Availability Dictates Cancer Metabolism-Based Therapeutic Responses to Non-oncology Drugs
Nutrient Availability Dictates Cancer Metabolism-Based Therapeutic Responses to Non-oncology Drugs
A novel TM4SF4-targeting therapeutic antibody candidate with antitumor activity by blocking IGF1R and CD44 signaling and downregulating PD-L1 and B7-H4
A novel TM4SF4-targeting therapeutic antibody candidate with antitumor activity by blocking IGF1R and CD44 signaling and downregulating PD-L1 and B7-H4